Skip to main content

x

Main navigation

HOME
Content

“The insights provided by the analysts are great”

Andrea Gnirke-Maier

Director New Product Planning

Morphosys

Click here for more information

Search

Breadcrumb

Home /
/
Duis quis nibh eget urna convallis

“Top quality, fast and so easy to use”

Andrea Gnirke-Maier

Director New Product Planning

Morphosys

Click here for more information

Duis quis nibh eget urna convallis

17 March 2017 / Comments

Submitted by

ApexOnco Editorial Team

on 17 March 2017

Recent Quick take

Jazz joins the KRAS band with Redx deal

7 February 2024
Gilead deals more checkpoint disappointment

7 February 2024
The pullback from RET inhibition

6 February 2024
Bristol shows its alnuctamab hand

5 February 2024
Bicycle rides onto its accelerated pathway

31 January 2024
ASCO-GU – subcutaneous Opdivo puts the pressure on Merck

30 January 2024
Roche walks away from Hookipa’s KRAS immunotherapy

29 January 2024
Kura’s PIPE dream

25 January 2024

Load More

Most Popular

CCR8 expectations

18 April 2024
ESMO 2023 – Pluvicto’s big splash gets an early preview

17 October 2023
Revolution pushes home its pan-KRAS advantage

27 February 2024
AstraZeneca's phase 3 TIGIT surprise

2 November 2023
ESMO 2023 – Revolution sets the bar in pan-KRAS inhibition

22 October 2023
The month ahead: May’s remaining events

14 May 2024

Subscribe to our newsletter

Contact
|
Terms & Conditions
|
Privacy Policy
|
Cookies Policy